Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.
The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth.
This report offers an overview of the market trends, drivers, and barriers with respect to the China Benign Prostatic Hyperplasia (BPH) Drugs market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Benign Prostatic Hyperplasia (BPH) Drugs market. Detailed analysis of key players, along with key growth strategies adopted by Benign Prostatic Hyperplasia (BPH) Drugs industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
GlaxoSmithKline
Eli Lilly
ADC Therapeutics
Sanofi
Astellas Pharma
Foresee Pharmaceuticals
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Bayer HealthCare
By Type:
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
5-Alpha-Reductase Inhibitors
By End-User:
Men
Women
By Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Benign Prostatic Hyperplasia (BPH) Drugs Market
-
1.3 Market Segment by Type
-
1.3.1 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Alpha-Blocker from 2016 to 2027
-
1.3.2 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors from 2016 to 2027
-
1.3.3 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of 5-Alpha-Reductase Inhibitors from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Men from 2016 to 2027
-
1.4.2 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Women from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 North China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 Central China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 South China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 East China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.5 Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.6 Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.7 Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Benign Prostatic Hyperplasia (BPH) Drugs Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Commercial Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Benign Prostatic Hyperplasia (BPH) Drugs by Major Types
-
3.4.1 Market Size and Growth Rate of Alpha-Blocker
-
3.4.2 Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors
-
3.4.3 Market Size and Growth Rate of 5-Alpha-Reductase Inhibitors
4 Segmentation of Benign Prostatic Hyperplasia (BPH) Drugs Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Benign Prostatic Hyperplasia (BPH) Drugs by Major End-Users
-
4.4.1 Market Size and Growth Rate of Benign Prostatic Hyperplasia (BPH) Drugs in Men
-
4.4.2 Market Size and Growth Rate of Benign Prostatic Hyperplasia (BPH) Drugs in Women
5 Market Analysis by Regions
-
5.1 China Benign Prostatic Hyperplasia (BPH) Drugs Production Analysis by Regions
-
5.2 China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on China Economy
6 North China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis
-
6.1 North China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types
-
6.2 North China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users
7 Central China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis
-
7.1 Central China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types
-
7.2 Central China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users
8 South China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis
-
8.1 South China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types
-
8.2 South China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users
9 East China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis
-
9.1 East China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types
-
9.2 East China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users
10 Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis
-
10.1 Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types
-
10.2 Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users
11 Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis
-
11.1 Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types
-
11.2 Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users
12 Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis
-
12.1 Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types
-
12.2 Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users
13 Major Players Profiles
-
13.1 GlaxoSmithKline
-
13.1.1 GlaxoSmithKline Company Profile and Recent Development
-
13.1.2 Market Performance
-
13.1.3 Product and Service Introduction
-
13.2 Eli Lilly
-
13.2.1 Eli Lilly Company Profile and Recent Development
-
13.2.2 Market Performance
-
13.2.3 Product and Service Introduction
-
13.3 ADC Therapeutics
-
13.3.1 ADC Therapeutics Company Profile and Recent Development
-
13.3.2 Market Performance
-
13.3.3 Product and Service Introduction
-
13.4 Sanofi
-
13.4.1 Sanofi Company Profile and Recent Development
-
13.4.2 Market Performance
-
13.4.3 Product and Service Introduction
-
13.5 Astellas Pharma
-
13.5.1 Astellas Pharma Company Profile and Recent Development
-
13.5.2 Market Performance
-
13.5.3 Product and Service Introduction
-
13.6 Foresee Pharmaceuticals
-
13.6.1 Foresee Pharmaceuticals Company Profile and Recent Development
-
13.6.2 Market Performance
-
13.6.3 Product and Service Introduction
-
13.7 Bristol-Myers Squibb
-
13.7.1 Bristol-Myers Squibb Company Profile and Recent Development
-
13.7.2 Market Performance
-
13.7.3 Product and Service Introduction
-
13.8 Valeant Pharmaceuticals
-
13.8.1 Valeant Pharmaceuticals Company Profile and Recent Development
-
13.8.2 Market Performance
-
13.8.3 Product and Service Introduction
-
13.9 Endo Pharmaceuticals
-
13.9.1 Endo Pharmaceuticals Company Profile and Recent Development
-
13.9.2 Market Performance
-
13.9.3 Product and Service Introduction
-
13.10 Bayer HealthCare
-
13.10.1 Bayer HealthCare Company Profile and Recent Development
-
13.10.2 Market Performance
-
13.10.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Alpha-Blocker from 2016 to 2027
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors from 2016 to 2027
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of 5-Alpha-Reductase Inhibitors from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2021
-
Figure Market Share by Type in 2027
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Men from 2016 to 2027
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Women from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2021
-
Figure Market Share by End-User in 2027
-
Figure North China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Central China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure East China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Benign Prostatic Hyperplasia (BPH) Drugs Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2020
-
Figure Market Share of TOP 5 Players in 2021
-
Figure Market Share of TOP 6 Players from 2016 to 2021
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Map of China
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Benign Prostatic Hyperplasia (BPH) Drugs
-
Figure Development Trends of Different Types
-
Table Commercial Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Benign Prostatic Hyperplasia (BPH) Drugs by Different Types from 2016 to 2027
-
Table Consumption Share of Benign Prostatic Hyperplasia (BPH) Drugs by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Alpha-Blocker
-
Figure Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors
-
Figure Market Size and Growth Rate of 5-Alpha-Reductase Inhibitors
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Benign Prostatic Hyperplasia (BPH) Drugs by Different End-Users from 2016 to 2027
-
Table Consumption Share of Benign Prostatic Hyperplasia (BPH) Drugs by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Men
-
Figure Market Size and Growth Rate of Women
-
Table China Benign Prostatic Hyperplasia (BPH) Drugs Production by Regions
-
Table China Benign Prostatic Hyperplasia (BPH) Drugs Production Share by Regions
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Production Share by Regions in 2016
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Production Share by Regions in 2021
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Production Share by Regions in 2027
-
Table China Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Regions
-
Table China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Regions
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Regions in 2016
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Regions in 2021
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Regions in 2027
-
Table North China Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2016 to 2027
-
Table North China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2016 to 2027
-
Figure North China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2016
-
Figure North China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2021
-
Figure North China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2027
-
Table North China Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2016 to 2027
-
Table North China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure North China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2016
-
Figure North China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2021
-
Figure North China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2027
-
Table Central China Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2016 to 2027
-
Table Central China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2016 to 2027
-
Figure Central China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2016
-
Figure Central China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2021
-
Figure Central China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2027
-
Table Central China Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2016 to 2027
-
Table Central China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Central China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2016
-
Figure Central China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2021
-
Figure Central China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2027
-
Table South China Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2016 to 2027
-
Table South China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2016 to 2027
-
Figure South China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2016
-
Figure South China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2021
-
Figure South China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2027
-
Table South China Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2016 to 2027
-
Table South China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure South China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2016
-
Figure South China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2021
-
Figure South China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2027
-
Table East China Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2016 to 2027
-
Table East China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2016 to 2027
-
Figure East China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2016
-
Figure East China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2021
-
Figure East China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2027
-
Table East China Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2016 to 2027
-
Table East China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure East China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2016
-
Figure East China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2021
-
Figure East China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2027
-
Table Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2016 to 2027
-
Table Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2016 to 2027
-
Figure Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2016
-
Figure Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2021
-
Figure Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2027
-
Table Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2016 to 2027
-
Table Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2016
-
Figure Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2021
-
Figure Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2027
-
Table Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2016 to 2027
-
Table Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2016 to 2027
-
Figure Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2016
-
Figure Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2021
-
Figure Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2027
-
Table Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2016 to 2027
-
Table Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2016
-
Figure Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2021
-
Figure Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2027
-
Table Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2016 to 2027
-
Table Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2016 to 2027
-
Figure Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2016
-
Figure Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2021
-
Figure Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types in 2027
-
Table Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2016 to 2027
-
Table Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2016
-
Figure Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2021
-
Figure Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of GlaxoSmithKline
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline
-
Figure Sales and Growth Rate Analysis of GlaxoSmithKline
-
Figure Revenue and Market Share Analysis of GlaxoSmithKline
-
Table Product and Service Introduction of GlaxoSmithKline
-
Table Company Profile and Development Status of Eli Lilly
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly
-
Figure Sales and Growth Rate Analysis of Eli Lilly
-
Figure Revenue and Market Share Analysis of Eli Lilly
-
Table Product and Service Introduction of Eli Lilly
-
Table Company Profile and Development Status of ADC Therapeutics
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of ADC Therapeutics
-
Figure Sales and Growth Rate Analysis of ADC Therapeutics
-
Figure Revenue and Market Share Analysis of ADC Therapeutics
-
Table Product and Service Introduction of ADC Therapeutics
-
Table Company Profile and Development Status of Sanofi
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi
-
Figure Sales and Growth Rate Analysis of Sanofi
-
Figure Revenue and Market Share Analysis of Sanofi
-
Table Product and Service Introduction of Sanofi
-
Table Company Profile and Development Status of Astellas Pharma
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Astellas Pharma
-
Figure Sales and Growth Rate Analysis of Astellas Pharma
-
Figure Revenue and Market Share Analysis of Astellas Pharma
-
Table Product and Service Introduction of Astellas Pharma
-
Table Company Profile and Development Status of Foresee Pharmaceuticals
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Foresee Pharmaceuticals
-
Figure Sales and Growth Rate Analysis of Foresee Pharmaceuticals
-
Figure Revenue and Market Share Analysis of Foresee Pharmaceuticals
-
Table Product and Service Introduction of Foresee Pharmaceuticals
-
Table Company Profile and Development Status of Bristol-Myers Squibb
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bristol-Myers Squibb
-
Figure Sales and Growth Rate Analysis of Bristol-Myers Squibb
-
Figure Revenue and Market Share Analysis of Bristol-Myers Squibb
-
Table Product and Service Introduction of Bristol-Myers Squibb
-
Table Company Profile and Development Status of Valeant Pharmaceuticals
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Valeant Pharmaceuticals
-
Figure Sales and Growth Rate Analysis of Valeant Pharmaceuticals
-
Figure Revenue and Market Share Analysis of Valeant Pharmaceuticals
-
Table Product and Service Introduction of Valeant Pharmaceuticals
-
Table Company Profile and Development Status of Endo Pharmaceuticals
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Endo Pharmaceuticals
-
Figure Sales and Growth Rate Analysis of Endo Pharmaceuticals
-
Figure Revenue and Market Share Analysis of Endo Pharmaceuticals
-
Table Product and Service Introduction of Endo Pharmaceuticals
-
Table Company Profile and Development Status of Bayer HealthCare
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bayer HealthCare
-
Figure Sales and Growth Rate Analysis of Bayer HealthCare
-
Figure Revenue and Market Share Analysis of Bayer HealthCare
-
Table Product and Service Introduction of Bayer HealthCare
-
